Parkinson's disease — adjunct to levodopa/carbidopa
adult
200 mg with each levodopa/carbidopa dose
200 mg with each levodopa/carbidopa dose
8 doses/day (1,600 mg/day)
Renal Undefined
Hepatic Caution — entacapone AUC and Cmax approximately doubled in documented liver disease
Limited clinical experience with daily doses above 1,600 mg.
Instructions
Always administer with levodopa/carbidopa — entacapone has no antiparkinsonian effect of its own
May take with or without food
Can be combined with immediate- or sustained-release levodopa/carbidopa
Levodopa dose reduction (average ~25%) often needed, especially if levodopa >=800 mg/day or preexisting moderate-severe dyskinesia
Withdraw slowly — rapid withdrawal may cause re-emergence of PD signs and an NMS-like syndrome (hyperpyrexia, confusion); adjust other dopaminergic therapy on discontinuation
Cautions
Ordinarily do not combine with non-selective MAOIs (phenelzine, tranylcypromine) — both catecholamine pathways inhibited; selective MAO-B inhibitors (selegiline) may be used